11.10
+2.24(+25.28%)
Currency In USD
| Previous Close | 8.86 |
| Open | 9.66 |
| Day High | 11.58 |
| Day Low | 9.66 |
| 52-Week High | 22.9 |
| 52-Week Low | 8.12 |
| Volume | 179,470 |
| Average Volume | 23,925 |
| Market Cap | 23.04M |
| PE | -1.27 |
| EPS | -8.72 |
| Moving Average 50 Days | 12.51 |
| Moving Average 200 Days | 14.04 |
| Change | 2.24 |
If you invested $1000 in Cadrenal Therapeutics, Inc. Common Stock (CVKD) since IPO date, it would be worth $179.61 as of December 05, 2025 at a share price of $11.1. Whereas If you bought $1000 worth of Cadrenal Therapeutics, Inc. Common Stock (CVKD) shares 1 year ago, it would be worth $830.22 as of December 05, 2025 at a share price of $11.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
GlobeNewswire Inc.
Dec 01, 2025 2:00 PM GMT
PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment
Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award
GlobeNewswire Inc.
Nov 19, 2025 1:00 PM GMT
PONTE VEDRA, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced its Chairman an
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
GlobeNewswire Inc.
Sep 29, 2025 8:30 PM GMT
PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced that it will parti